Sunshine Biopharma’s (SBFM) Buy Rating Reiterated at Aegis

Aegis restated their buy rating on shares of Sunshine Biopharma (NASDAQ:SBFM) in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has a $7.00 target price on the stock.

A number of other research firms also recently weighed in on SBFM. Wall Street Zen raised Sunshine Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, July 26th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Sunshine Biopharma in a research note on Wednesday. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Sunshine Biopharma has a consensus rating of “Hold” and an average target price of $7.00.

Sunshine Biopharma Price Performance

SBFM opened at $1.55 on Wednesday. Sunshine Biopharma has a fifty-two week low of $1.17 and a fifty-two week high of $3.90. The business has a 50-day moving average of $1.48 and a 200-day moving average of $1.49. The company has a market capitalization of $7.07 million, a PE ratio of -0.01 and a beta of 1.48.

Sunshine Biopharma (NASDAQ:SBFM) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.39) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.28). Sunshine Biopharma had a negative return on equity of 26.04% and a negative net margin of 17.35%.The firm had revenue of $9.41 million for the quarter, compared to analysts’ expectations of $12.10 million.

Institutional Trading of Sunshine Biopharma

A hedge fund recently bought a new stake in Sunshine Biopharma stock. Altium Capital Management LLC acquired a new position in shares of Sunshine Biopharma, Inc. (NASDAQ:SBFM) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 50,466 shares of the company’s stock, valued at approximately $96,000. Sunshine Biopharma makes up about 0.2% of Altium Capital Management LLC’s investment portfolio, making the stock its 21st biggest holding. Altium Capital Management LLC owned approximately 1.86% of Sunshine Biopharma as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 41.98% of the company’s stock.

About Sunshine Biopharma

Sunshine Biopharma, Inc, a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products.